Bristol-Myers Squibb Company (BMY) : 6 brokerage houses believe that Bristol-Myers Squibb Company (BMY) is a Strong Buy at current levels. 9 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Bristol-Myers Squibb Company (BMY). Zacks Investment Research suggests a Hold with a rank of 3. 2 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 17 Wall Street Analysts endorse the stock as a Hold with a rating of 2.53.
Bristol-Myers Squibb Company (BMY) : The highest level Bristol-Myers Squibb Company (BMY) is projected to reach is $100 for the short term and the lowest estimate is at $48. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $70.21 and the possibility the share price can swing is $13.06.
For the current week, the company shares have a recommendation consensus of Buy. Bristol-Myers Squibb Company (NYSE:BMY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $60.70 and $60.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $61.13. The buying momentum continued till the end and the stock did not give up its gains. It closed at $60.97, notching a gain of 0.64% for the day. The total traded volume was 14,576,344 . The stock had closed at $60.58 on the previous day.
In a related news,The director of Bristol Myers Squibb Co, Andreotti Lamberto sold 23,200 shares at $74.65 on July 7, 2016. The Insider selling transaction had a total value worth of $1,731,880. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.